Showing 1091-1100 of 9359 results for "".
- Syneron Introduces PicoWay Resolvehttps://practicaldermatology.com/news/syneron-introduces-picoway-resolve/2458850/Syneron Medical Ltd. introduced the PicoWay Resolve™, a dual wavelength fractional modality for the PicoWay picosecond laser, at the 24th European Academy of Dermatology and Venereology (EADV) Congress in Copenhagen, Denmark, October 7-11, 2015. The launch of the new Resolve fractional picosecond m…
- Report: Prescription Dermatological Drug Market Exceeds 21 Billion Dollarshttps://practicaldermatology.com/news/report-prescription-dermatological-drug-market-exceeds-21-billion-dollars/2458870/The worldwide market for prescription dermatological drugs exceeded $21 billion last year, according to a report from Kalorama Information. The market research firm said field of dermatology is currently experiencing a busy and interesting period and, as a result, the range of therapeutic options a…
- Report Predicts Growth in Global Dermatology Diagnostic Devices Market 2015-2019https://practicaldermatology.com/news/report-predicts-growth-in-global-dermatology-diagnostic-devices-market-2015-2019/2458869/A recently published report, Global Dermatology Diagnostic Devices Market 2015-2019, which was prepared based on an in-depth market analysis with inputs from industry experts, forecasts the global dermatology diagnostics devices market to grow at a CAGR of 9.1 percent over the period 2014-2019. Th…
- FDA Approves Humira for Moderate to Severe Hidradenitis Suppurativahttps://practicaldermatology.com/news/fda-approves-humira-for-moderate-to-severe-hidradenitis-suppurativa/2458873/The FDA approved AbbVie’s HUMIRA® (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa (HS). HUMIRA is now the first and only FDA-approved therapy for adults with HS. Earlier this year, the FDA granted HUMIRA orphan drug designation for the treatment of moderate to severe …
- Cynosure to Host Investor Event to Introduce SculpSurehttps://practicaldermatology.com/news/cynosure-to-host-investor-event-to-introduce-sculpsure/2458877/Cynosure, Inc. will host an investor event in New York City on Tuesday, September 15 to introduce SculpSure™, the only FDA-cleared hyperthermic laser treatment for non-invasive fat reduction. The Company will provide a live webcast of the event presentations from approximately 10:00 a.m. to 12:30 p…
- MEG 21 with Supplamine Now Available in Treatment Rooms with New Professional Size Dispensershttps://practicaldermatology.com/news/meg-21-with-supplamine-now-available-in-treatment-rooms-with-new-professional-size-dispensers/2458892/MEG 21 with Supplamine is a science-based company specializing in skin products for the face, neck, décolleté, and arms that uniquely remove toxic sugar from skin. Dynamis Skin Science, the parent company, was founded in 1997, based on the work of scientists initially working at Fox Chase Cancer Ce…
- Almirall Completes Investment in Suneva Medicalhttps://practicaldermatology.com/news/almirall-completes-investment-in-suneva-medical/2458900/Barcelona-based Almirall, a global pharmaceutical company, has closed a $15 million in Series C equity investment in Suneva Medical, Inc., marketer of Bellafill®. This product is the only dermal filler on the market that is FDA approved proven to be safe and effective for the correction of moderate…
- ASDS Skin Cancer Program Honoredhttps://practicaldermatology.com/news/asds-skin-cancer-program-honored/2458901/A skin cancer screening program offered by the American Society for Dermatologic Surgery has been commended with a national 2015 Power of A award for “helping to make the world a better place.” The Choose Skin Health program has been named a Power of A Gold Award winner by the American Society of …
- Encore Dermatology, Inc.: A New Specialty Dermatology Company Launcheshttps://practicaldermatology.com/news/encore-dermatology-inc-a-new-specialty-dermatology-company/2458942/Encore Dermatology, Inc. announced has begun to commercialize Hylatopic®, Tetrix™, and BenzEFoam™, three established topical dermatology products acquired from Valeant Pharmaceuticals North America, LLC and certain of its affiliates. Encore Dermatology, Inc. is a privately held company headquarter…
- Galderma to Enter Nutraceutical Markethttps://practicaldermatology.com/news/galderma-to-enter-nutraceutical-market/2458954/Galderma entred into the nutraceutical market through the acquisition of certain assets of Inneov Group. Relevant Inneov products are marketed under the brand names Nutri-Care D, Duocap, Densilogy, Densilogy Men, Fermete, Fermete Aox, Firmness, Pre-Hyaluron 465, Solar and Sun Sensitivity. “The nut…